Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Teva Pharmaceutical Industries Ltd (NYSE:TEVA)

49.47
Delayed Data
As of Sep 27
 -0.80 / -1.59%
Today’s Change
48.01
Today|||52-Week Range
66.55
-24.63%
Year-to-Date
The Zacks Analyst Blog Highlights: Teva Pharmaceutical Industries, Intel, Sanofi, Alp...
Sep 27 / Zacks.com - Paid Partner Content
Regeneron, Teva Collaborate to Develop Chronic Pain Drug
Sep 21 / Zacks.com - Paid Partner Content
Clinton, Trump Share Big-Pharma Attack Goals, Andrew Left Says
Sep 26 / TheStreet.com - Paid Partner Content
Teva Presents Top-Line Data from Huntington Disease Study
Sep 20 / Zacks.com - Paid Partner Content
Andrew Left Says Trump and Clinton Agree on Just One Thing
Sep 26 / TheStreet.com - Paid Partner Content
Intel and Teva Partner on Cloud-based Healthcare Solutions
Sep 16 / Zacks.com - Paid Partner Content
The Internet of Medical Things: 6 Stocks in Focus
Sep 26 / Zacks.com - Paid Partner Content
Teva/Intel Tie up for Huntington's Disease Technology Platform
Sep 16 / Zacks.com - Paid Partner Content
3 Dirt-Cheap Dividend Stocks You Can Buy Right Now
Sep 24 / MotleyFool.com - Paid Partner Content
Pharma Stock Roundup: Acquisitions & Deals Pick Up Pace, Aerie Up on Positive Data
Sep 16 / Zacks.com - Paid Partner Content
Teva: This Is No Generic Downtrend
Sep 23 / TheStreet.com - Paid Partner Content
Generic EpiPen coming for $300, as Mylan responds to outrage
Aug 29 / CNNMoney.com
Teva Reports Positive Phase III Tardive Dyskinesia Data
Sep 23 / Zacks.com - Paid Partner Content